Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Relapsed/Unresectable High-grade Osteosarcoma
NCT02711007Phase 3Completed
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Rivoceranib in osteosarcoma (OS). Primary endpoints: Progression-Free Survival at 4 months and Objective Response Rate at 3 months. Started Mar 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT02711007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711007.